Investigational injection to delay early Alzheimer’s disease progression

UniSC Clinical Trials is conducting a trial to evaluate a new investigational injection aimed at slowing the progression of early Alzheimer’s disease. We are seeking individuals aged 65 to 80 years who are willing to take a blood test to check for biomarkers linked to early Alzheimer’s. If confirmed, they may qualify to join the trial.

This is a phase 3 clinical trial that aims to evaluates whether the investigational treatment can slow or delay the progression of early Alzheimer’s disease by targeting and reducing amyloid plaque in the brain.

This study includes a focus on the phosphorylated tau (p-tau) biomarker, which emerging research suggests may help diagnose and monitor the progression of Alzheimer’s disease. Elevated levels of p-tau in blood are closely associated with the presence of amyloid plaques in the brain and may provide a non-invasive way to identify early-stage Alzheimer’s disease. By incorporating p-tau measurement, this trial aims to enhance early detection, improve participant selection, and evaluate the investigational treatment’s effectiveness in reducing amyloid-related pathology.

The trial will be overseen by Principal Investigator Dr Nischal Sahai at our South Bank clinic in Brisbane and supported by our experienced clinical trials staff.

We are seeking applications from people who

• are aged between 65 and 80 years old
• could have early Alzheimer’s disease or may be at risk of developing symptoms of Alzheimer’s disease
• are willing to take a blood test to check for an Alzheimer’s disease biomarker
• have a reliable study partner to accompany them throughout the trial and attend all clinic visits
• are able to have magnetic resonance imaging (MRI) scans
• can attend up to 16 visits over up to 5 years at our South Bank clinic in Brisbane or our Birtinya clinic on the Sunshine Coast.

If you have any patients who fit the criteria and would be suitable for this clinical trial, we would appreciate your consideration of their participation.

Patients will be compensated for their time on the trial. All trial-related treatment is of no cost to participants. Please do not hesitate to contact us on (07) 5409 8640 for further information.